Drug Profile
Research programme: adenosine A2A modulators - OSI Pharmaceuticals
Latest Information Update: 19 Jul 2006
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class
- Mechanism of Action Adenosine A2 receptor antagonists; Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Parkinson's disease
Most Recent Events
- 19 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 19 Jul 2006 No development reported - Preclinical for Parkinson's disease in USA (unspecified route)
- 26 Jun 2002 This programme is still in active development